Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372446 · ClinicalTrials.gov registry record
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency
A clinical trial of Autosomal Recessive Hypophosphatemic Rickets Type 2 and Generalized Arterial Calcification in Infancy, sponsored by Inozyme Pharma.
- Completed
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT04372446: Completed study of Autosomal Recessive Hypophosphatemic Rickets Type 2 and Generalized Arterial Calcification in Infancy, sponsored by Inozyme Pharma.
NCT04372446 is a study of Autosomal Recessive Hypophosphatemic Rickets Type 2 and Generalized Arterial Calcification in Infancy that has completed, run by Inozyme Pharma. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04372446, a study of Autosomal Recessive Hypophosphatemic Rickets Type 2 and Generalized Arterial Calcification in Infancy, has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
To date, the investigators lack characterization of, the burden of, and the systemic progression of disease in ENPP1 deficiency and ABCC6 deficiency from a patient and/or parent perspective. This study aims to document this characterization, progression as well as the burden of disease. Link to the study registration- https://www.engagehealth.com/survey/TakeSurvey.aspx?SurveyID=8252n62
Primary Outcome
The burden of disease through the eyes/voice of the patient and or caregiver will be collected and analyze for improved understanding
Conditions Studied
Study Locations (1)
Minnesota
- Engage Health - Eagan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-05-06 |
| Est. Completion | 2020-09-30 |
What the finished NCT04372446 record still lists
NCT04372446 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 2 conditions, with Autosomal Recessive Hypophosphatemic Rickets Type 2 appearing as the primary indexed condition, and to 0 interventions.
NCT04372446 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04372446 about?
NCT04372446 is a clinical study titled "Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency". To date, the investigators lack characterization of, the burden of, and the systemic progression of disease in ENPP1 deficiency and ABCC6 deficiency from a patient and/or parent perspective. This study aims to document this characterization, progression as well as the burden of disease. Link to the ...
What is the current status of trial NCT04372446?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2020-05-06. Estimated completion is 2020-09-30.
What conditions does trial NCT04372446 study?
This clinical trial studies the following conditions: Autosomal Recessive Hypophosphatemic Rickets Type 2, Generalized Arterial Calcification in Infancy.
Who is sponsoring clinical trial NCT04372446?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04372446 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Recessive Hypophosphatemic Rickets Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI